Anifrolumab

 

                                                                TULIP: Clinical Trial

                                                                         Anifrolumab 

Clinical Trial To Practice 

Anifrolumab 

Blocks Interferon Signalling 

Theory To Practice

Saphnelo 

The U.S. Food and Drug Administration (FDA) approved a subcutaneous self-administration option for AstraZeneca's Saphnelo (anifrolumab) on April 27, 2026. 

Snapshot